{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:51:00Z","timestamp":1789026660650,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1124\/dmd.109.028746","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T02:54:56Z","timestamp":1257216896000},"page":"241-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin"],"prefix":"10.1016","volume":"38","author":[{"given":"Sara K.","family":"Quinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroonrut","family":"Lucksiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christopher","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.028746_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol Ind Health"},{"key":"10.1124\/dmd.109.028746_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/dmd.105.008730","article-title":"Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole","volume":"34","author":"Chien","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/j.1552-4604.1993.tb05613.x","article-title":"Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial","volume":"33","author":"Chu","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib4","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1128\/AAC.36.11.2447","article-title":"Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses","volume":"36","author":"Chu","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.109.028746_bib5","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.109.028746_bib6","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)08537-X","article-title":"Metabolism and disposition of clarithromycin in man","volume":"18","author":"Ferrero","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin","volume":"24","author":"Fromm","year":"1996","journal-title":"Hepatology"},{"key":"10.1124\/dmd.109.028746_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.106.106013","article-title":"Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism","volume":"318","author":"Galetin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.028746_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/dmd.107.018713","article-title":"Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations","volume":"36","author":"Gertz","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib12","article-title":"Duration of CYP3A inhibition by clarithromycin","volume":"71","author":"Gorski","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.105.007658","article-title":"Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement","volume":"34","author":"Hallifax","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.41.5.898","article-title":"Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects","volume":"41","author":"Hsu","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.109.028746_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2125.2009.03386.x","article-title":"In vitro and in vivo glucuronidation of midazolam in humans","volume":"67","author":"Hyland","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/dmd.31.7.945","article-title":"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes","volume":"31","author":"Ito","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.106.014613","article-title":"Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5)","volume":"35","author":"Jones","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","article-title":"Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein","volume":"16","author":"Kim","year":"1999","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.109.028746_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-199410000-00003","article-title":"CYP3A gene expression in human gut epithelium","volume":"4","author":"Kolars","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.109.028746_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpt1978243316","article-title":"Time-course of interaction between carbamazepine and clonazepam in normal man","volume":"24","author":"Lai","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.028746_bib28","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie.\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/dmd.104.002469","article-title":"Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?","volume":"33","author":"Paine","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.10.002","article-title":"Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4\/5 activity and expression","volume":"77","author":"Pinto","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-005-0091-x","article-title":"Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate","volume":"62","author":"Polasek","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/17425255.3.3.321","article-title":"In vitro approaches to investigate mechanism-based inactivation of CYP enzymes","volume":"3","author":"Polasek","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.109.028746_bib33","first-page":"623","article-title":"Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1124\/mol.51.5.741","article-title":"Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1\u03b1,25-dihydroxyvitamin D3","volume":"51","author":"Schmiedlin-Ren","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2133\/dmpk.18.104","article-title":"CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites","volume":"18","author":"Suzuki","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.109.028746_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.2000.00140.x","article-title":"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model","volume":"49","author":"Takanaga","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.109.028746_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.028746_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0022-3565(25)22834-8","article-title":"Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.109.028746_bib39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","article-title":"In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude","volume":"33","author":"Venkatakrishnan","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib40","first-page":"287","article-title":"Age and sex effect on the recovery time of CYP3A inhibition by clarithromycin","volume":"36","author":"Wang","year":"2004","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.109.028746_bib41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/dmd.104.001834","article-title":"Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil","volume":"33","author":"Wang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.109.028746_bib43","first-page":"400","article-title":"Interaction between midazolam and clarithromycin: comparison with azithromycin","volume":"34","author":"Yeates","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.109.028746_bib44","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.109.026658","article-title":"Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.028746_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389200043335450","article-title":"Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4","volume":"5","author":"Zhou","year":"2004","journal-title":"Curr Drug Metab"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624022761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624022761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.028746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:47:13Z","timestamp":1739897233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624022761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0090955624022761"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.028746","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.028746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}